Optic Nerve Sonography to Monitor Intracranial Pressure After Ischemic sTrokE - The ONSITE Study
NCT ID: NCT06939114
Last Updated: 2025-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2019-01-01
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Between Optic Nerve Sheath Diameter and Neurological Deficit in Adult Patients With Suspected Ischemic Stroke
NCT06492681
Intracranial Pressure and Optic Nerve Sheath Diameter With CLOSED Bundle
NCT06057155
Brain PERfusion Evaluation by Contrast-Enhanced UltraSound
NCT05893407
Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein
NCT07053631
Observational Study of Safety and Outcomes After Minimally Invasive Surgery for Intracerebral Hemorrhage
NCT01920763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IH is a life-threatening emergency that demands immediate medical or surgical action. As it is not possible to predict the course of intracerebral pressure increase in patients at risk, it is necessary to monitor these patients closely. However, clinical observation of neurological symptoms may be hampered, as stroke patients often require pain or anxiolytic medications or suffer from typical comorbidities of stroke, such as infection, cardiac diseases, or delirium, which limit judgment of neurological symptoms. Despite the limitations of clinical symptom prediction for IH, ICP is not routinely monitored in stroke patients as invasive intracranial devices, the current gold standard for ICP monitoring have several drawbacks that limit their routine application. Intracranial ICP monitors require a neurosurgical intervention, which may not always be feasible or contraindicated in several conditions such as coagulopathy and thrombocytopenia. Furthermore, ICP monitors are associated with complications such as hemorrhages (1.1-5.8% of cases), infection (0-15% of cases) or monitor malfunction (6.3-40% of cases).
Because of these limitations, noninvasive methods to measure ICP have been eagerly sought. Se-rial computer tomography (CT) or Magnetic Resonance Imaging (MRI) are applied to detect in-creased ICP in patients at risk. However, imaging is expensive, potential harmful to patients due to radiation or necessity to lie supine and still for a prolonged period and have limited availability. As such, their use is restricted as well. Furthermore there are studies suggesting that CT scans might have a poor sensitivity for detection of IH.
Ultrasonography is an alternative tool to measure ICP non-invasively. Ultrasonography is a low cost, simple bedside tool, widely available in emergency rooms as well as on stroke units. Optic nerve sonography (ONS) to measure the optic nerve sheath diameter (ONSD) has been developed and suggested as an alternative sonographic method to detect IH. ONS utilizes the fact that the optic nerve sheath, which is readily visualized by transorbital ultrasound, is filled with spinal fluid and grows in diameter according to ICP. To perform ONS, the patient is placed in a position 20̊ supine to horizontal. The probe is then placed on the temporal side of the closed eyelid without pressure to avoid any damage to the eye. The position of the probe is then adjusted until the entry of the optic nerve into the globe of the eye is visible. ONSD is measured 3 mm behind the globe, as this position shows the greatest distension of the optic sheath in IH patients and thus has become the standard measurement point.
The method is quickly learned and a trained operator can perform measurement of ONSD in both eyes in less than 4 minutes. In current clinical practice, ONS has been used in intensive care setting to monitor ICP and diagnose brain death in brain trauma patients. ONS is also used in other neurological diseases, such as idiopathic intracranial hypertension. It was shown in several studies, as well as meta-analyses that ONS derived measurements of intracranial hypertension can be performed with good intra- and interobserver reliability. In a meta-analysis, in which ONDS was compared to invasive ICP measurements, ONSD showed good test accuracy with a pooled sensitivity of 90% and pooled specificity of 85%. When compared to CT scan, ONSD showed good accuracy for IH as well, with a sensitivity of 95.6% and specificity of 92.3%. ONSD can also be used to rapidly assess the success of therapeutic interventions. For example, patients with idiopathic intracranial hypertension showed a significantly reduced ONSD directly af-ter lumbar puncture with therapeutic removal of 30-50 ml of cerebrospinal fluid (CSF).
Several studies raised the question of which cut-off value should be used for the ONSD in healthy individuals. Earlier studies that compared ONSD to CT results suggested a upper normal value of 4.5 mm for individuals aged ≤1 year and 5.0 mm for those aged \>1 year. More recent studies, however, comparing ONSD to invasive ICP measurements, suggested that a cut-off value of 5.7-6.0mm provided the best accuracy and that values above that cut off should alert the clinician of IH.
Preliminary data from routine evaluation of ONSD in patients with stroke and ICH showed significantly increased ONSD on the side of stroke compared to the contralateral side. The investigators also tested for the feasibility of the method in patients with diagnosed idiopathic intracranial hyper-tension, which were found to have larger ONSD than healthy individuals on both sides. In each patient, 3 individual measurements per eye were averaged.
The goal of this study is to improve stroke patient care by helping to investigate whether ONS is a feasible tool to diagnose IH after stroke, as IH is one of the most troublesome and life-threatening complications of large-vessel ischemic stroke. It is critical that the clinician does not miss rising ICP so that life-saving treatment is not delayed. ONS measurement of ICP is an accurate, widely avail-able and easy to learn method to detect IH and has been successfully used in clinical practice in several fields of neurology. Its value in acute stroke care, however, remains uncertain. The investigators have tested ONS derived ONSD measurements and have confirmed the feasibility to use this parameter. If ONSD thresholds can be established to detect IH early after stroke, it could be further tested in a clinical trial to aid in decision making for hemicraniectomy in stroke patients.
This study aims to investigate the hypothesis that ONS is a feasible method to detect IH in stroke patients. To this end, the primary objective is to observe the changes in ONSD after large-vessel ischemic stroke and in the presence of IH.
The second objective is to derive a cut-off value for ONSD that best predicts the presence of IH in stroke patients and to assess whether this cut-off value would be able to detect IH before clinical changes occur (assessed by the Glasgow Coma Scale (GCS) and/or National Institutes of Health Stroke Scale (NIHSS) in patients at risk). This cut-off value could be the base for a future clinical trial to evaluate the diagnostic performance of this method in stroke patients. In addition, the investigators aim to investigate the predictive value of the ONSD in the clinical outcome after stroke (as derived from the modified Rankin Scale (mRS) and NIHSS after 3 month).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stroke
Patient with acute ischemic stroke
No interventions assigned to this group
Non-Stroke, non-IH controls
Patient without acute stroke or history of intracranial hypertension
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consent according to the regulations of research in an emergency situation
* For non-Control patients: Acute ischemic stroke within 24 hours of recruitment
Exclusion Criteria
* Known history of intracranial hypertension
* Contra-indications on ethical grounds
* Expected or known non-compliance to participate in the observational study, severe drug- or/and alcohol abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Susanne Wegener
Prof. Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bauerle J, Nedelmann M. Sonographic assessment of the optic nerve sheath in idiopathic intracranial hypertension. J Neurol. 2011 Nov;258(11):2014-9. doi: 10.1007/s00415-011-6059-0. Epub 2011 Apr 28.
Bauerle J, Lochner P, Kaps M, Nedelmann M. Intra- and interobsever reliability of sonographic assessment of the optic nerve sheath diameter in healthy adults. J Neuroimaging. 2012 Jan;22(1):42-5. doi: 10.1111/j.1552-6569.2010.00546.x. Epub 2010 Dec 1.
Toscano M, Spadetta G, Pulitano P, Rocco M, Di Piero V, Mecarelli O, Vicenzini E. Optic Nerve Sheath Diameter Ultrasound Evaluation in Intensive Care Unit: Possible Role and Clinical Aspects in Neurological Critical Patients' Daily Monitoring. Biomed Res Int. 2017;2017:1621428. doi: 10.1155/2017/1621428. Epub 2017 Mar 21.
Tayal VS, Neulander M, Norton HJ, Foster T, Saunders T, Blaivas M. Emergency department sonographic measurement of optic nerve sheath diameter to detect findings of increased intracranial pressure in adult head injury patients. Ann Emerg Med. 2007 Apr;49(4):508-14. doi: 10.1016/j.annemergmed.2006.06.040. Epub 2006 Sep 25.
Ohle R, McIsaac SM, Woo MY, Perry JJ. Sonography of the Optic Nerve Sheath Diameter for Detection of Raised Intracranial Pressure Compared to Computed Tomography: A Systematic Review and Meta-analysis. J Ultrasound Med. 2015 Jul;34(7):1285-94. doi: 10.7863/ultra.34.7.1285.
Hansen HC, Helmke K. The subarachnoid space surrounding the optic nerves. An ultrasound study of the optic nerve sheath. Surg Radiol Anat. 1996;18(4):323-8. doi: 10.1007/BF01627611.
Hansen HC, Helmke K. Validation of the optic nerve sheath response to changing cerebrospinal fluid pressure: ultrasound findings during intrathecal infusion tests. J Neurosurg. 1997 Jul;87(1):34-40. doi: 10.3171/jns.1997.87.1.0034.
Galetta S, Byrne SF, Smith JL. Echographic correlation of optic nerve sheath size and cerebrospinal fluid pressure. J Clin Neuroophthalmol. 1989 Jun;9(2):79-82.
Dubourg J, Javouhey E, Geeraerts T, Messerer M, Kassai B. Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis. Intensive Care Med. 2011 Jul;37(7):1059-68. doi: 10.1007/s00134-011-2224-2. Epub 2011 Apr 20.
Ropper AH, Shafran B. Brain edema after stroke. Clinical syndrome and intracranial pressure. Arch Neurol. 1984 Jan;41(1):26-9. doi: 10.1001/archneur.1984.04050130032017.
Schwab S, Aschoff A, Spranger M, Albert F, Hacke W. The value of intracranial pressure monitoring in acute hemispheric stroke. Neurology. 1996 Aug;47(2):393-8. doi: 10.1212/wnl.47.2.393.
Wijdicks EF, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, Schwab S, Smith EE, Tamargo RJ, Wintermark M; American Heart Association Stroke Council. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Apr;45(4):1222-38. doi: 10.1161/01.str.0000441965.15164.d6. Epub 2014 Jan 30.
Heiss WD. Malignant MCA Infarction: Pathophysiology and Imaging for Early Diagnosis and Management Decisions. Cerebrovasc Dis. 2016;41(1-2):1-7. doi: 10.1159/000441627. Epub 2015 Nov 19.
Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996 Apr;53(4):309-15. doi: 10.1001/archneur.1996.00550040037012.
Hofmeijer J, Algra A, Kappelle LJ, van der Worp HB. Predictors of life-threatening brain edema in middle cerebral artery infarction. Cerebrovasc Dis. 2008;25(1-2):176-84. doi: 10.1159/000113736. Epub 2008 Jan 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01946
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.